NeOnc Technologies Holdings Says FDA Reschedules End-Of-Phase 1 Meeting For Oral NEO212 To November 23
Meeting will address Phase 2 study design and potential regulatory pathways for oral NEO212CALABASAS, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the

